NASDAQ:COLLCollegium Pharmaceutical Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Collegium Pharmaceutical Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.92 +0.03 (+0.16 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$18.72Now: $18.92▼$19.5850-Day Range$15.78MA: $17.19▼$18.9252-Week Range$10.41Now: $18.92▼$25.59Volume426,700 shsAverage Volume554,702 shsMarket Capitalization$653.23 millionP/E RatioN/ADividend YieldN/ABeta0.97 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting. The company offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. Furhter, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingCollegium Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 6 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.71, Collegium Pharmaceutical has a potential upside of 51.8% from its current price of $18.92.Amount of Analyst CoverageCollegium Pharmaceutical has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCollegium Pharmaceutical has received 322 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCollegium Pharmaceutical has received 320 “underperform” votes. (Add your “underperform” vote.)Community SentimentCollegium Pharmaceutical has received 50.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote “Outperform” if you believe COLL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCollegium Pharmaceutical does not currently pay a dividend.Dividend GrowthCollegium Pharmaceutical does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,235,800.00 in company stock.Percentage Held by InsidersOnly 8.08% of the stock of Collegium Pharmaceutical is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Collegium Pharmaceutical are expected to grow by 135.00% in the coming year, from $0.80 to $1.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Collegium Pharmaceutical is -1,892.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Collegium Pharmaceutical is -1,892.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCollegium Pharmaceutical has a PEG Ratio of 1.14. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCollegium Pharmaceutical has a P/B Ratio of 7.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:COLL Previous Symbol CUSIPN/A CIK1267565 Webwww.collegiumpharma.com Phone781-713-3699Debt Debt-to-Equity Ratio1.53 Current Ratio0.99 Quick Ratio0.92Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio23.65 P/E Growth1.14 Sales & Book Value Annual Sales$296.70 million Price / Sales2.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book7.25Profitability EPS (Most Recent Fiscal Year)($0.68) Net Income$-22,720,000.00 Net Margins0.07% Return on Equity0.17% Return on Assets0.04%Miscellaneous Employees266 Outstanding Shares34,526,000Market Cap$653.23 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $18.92 +0.03 (+0.16 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive COLL News and Ratings via Email Sign-up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions How has Collegium Pharmaceutical's stock been impacted by Coronavirus (COVID-19)? Collegium Pharmaceutical's stock was trading at $17.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, COLL shares have increased by 7.7% and is now trading at $18.92. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Collegium Pharmaceutical? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Collegium Pharmaceutical. When is Collegium Pharmaceutical's next earnings date? Collegium Pharmaceutical is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Collegium Pharmaceutical. How were Collegium Pharmaceutical's earnings last quarter? Collegium Pharmaceutical Inc (NASDAQ:COLL) released its earnings results on Wednesday, August, 5th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.24 by $0.01. Collegium Pharmaceutical had a return on equity of 0.17% and a net margin of 0.07%. View Collegium Pharmaceutical's earnings history. What price target have analysts set for COLL? 9 brokerages have issued 12 month price targets for Collegium Pharmaceutical's shares. Their forecasts range from $8.00 to $43.00. On average, they anticipate Collegium Pharmaceutical's stock price to reach $28.71 in the next year. This suggests a possible upside of 51.8% from the stock's current price. View analysts' price targets for Collegium Pharmaceutical. Has Collegium Pharmaceutical been receiving favorable news coverage? Media headlines about COLL stock have trended extremely negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a daily sentiment score of -4.1 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Collegium Pharmaceutical. Are investors shorting Collegium Pharmaceutical? Collegium Pharmaceutical saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 4,390,000 shares, an increase of 82.2% from the January 31st total of 2,410,000 shares. Based on an average trading volume of 587,500 shares, the days-to-cover ratio is currently 7.5 days. Approximately 14.5% of the company's shares are sold short. View Collegium Pharmaceutical's Short Interest. Who are some of Collegium Pharmaceutical's key competitors? Some companies that are related to Collegium Pharmaceutical include Amarin (AMRN), Deciphera Pharmaceuticals (DCPH), Pacira Biosciences (PCRX), Taro Pharmaceutical Industries (TARO), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Xencor (XNCR), Uniqure (QURE), Ligand Pharmaceuticals (LGND), Aurinia Pharmaceuticals (AUPH), Intercept Pharmaceuticals (ICPT) and IGM Biosciences (IGMS). View all competitors. What other stocks do shareholders of Collegium Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Canopy Growth (CGC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Bausch Health Companies (BHC) and Intercept Pharmaceuticals (ICPT). Who are Collegium Pharmaceutical's key executives? Collegium Pharmaceutical's management team includes the following people: Mr. Michael Thomas Heffernan, Co-Founder & Chairman (Age 55)Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)Ms. Shirley R. Kuhlmann, Exec. VP, Gen. Counsel & Sec. (Age 35) When did Collegium Pharmaceutical IPO? (COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers. What is Collegium Pharmaceutical's stock symbol? Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL." Who are Collegium Pharmaceutical's major shareholders? Collegium Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (1.68%), Emerald Mutual Fund Advisers Trust (1.53%), Mesirow Financial Investment Management Equity Management (0.86%), Bank of Montreal Can (0.69%), Bank of New York Mellon Corp (0.54%) and WINTON GROUP Ltd (0.52%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan and Scott Dreyer. View institutional ownership trends for Collegium Pharmaceutical. Which major investors are selling Collegium Pharmaceutical stock? COLL stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Goldman Sachs Group Inc., Smith Asset Management Group LP, ClariVest Asset Management LLC, Fisher Asset Management LLC, Dupont Capital Management Corp, and Mesirow Financial Investment Management Equity Management. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, David Hirsch, Joseph Ciaffoni, Michael Thomas Heffernan, and Scott Dreyer. View insider buying and selling activity for Collegium Pharmaceutical. Which major investors are buying Collegium Pharmaceutical stock? COLL stock was acquired by a variety of institutional investors in the last quarter, including Mackay Shields LLC, Cadence Capital Management LLC, WINTON GROUP Ltd, Chartwell Investment Partners LLC, 1492 Capital Management LLC, Knott David M, Monarch Partners Asset Management LLC, and Swiss National Bank. View insider buying and selling activity for Collegium Pharmaceutical. How do I buy shares of Collegium Pharmaceutical? Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Collegium Pharmaceutical's stock price today? One share of COLL stock can currently be purchased for approximately $18.92. How big of a company is Collegium Pharmaceutical? Collegium Pharmaceutical has a market capitalization of $653.23 million and generates $296.70 million in revenue each year. The specialty pharmaceutical company earns $-22,720,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe. What is Collegium Pharmaceutical's official website? The official website for Collegium Pharmaceutical is www.collegiumpharma.com. How can I contact Collegium Pharmaceutical? Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
